Neuren Raises Trofinetide Income Guidance
Neuren Pharmaceuticals lifted its full-year 2026 income outlook for trofinetide, driven by strong Q3 sales of the Alzheimer's-related therapy and a milestone payment.
Updated on Nov. 5, 2026 in Alzheimer’s
Neuren Pharmaceuticals upgraded its full-year 2026 income guidance for trofinetide to US$91 million to US$93 million, up from US$53 million to US$56 million. The increase follows Acadia Pharmaceuticals reporting Q3 2026 DAYBUE net sales of US$140 million.
Why it matters
The guidance upgrade reflects strong commercial performance of trofinetide through partner Acadia, along with a US$35 million milestone payment tied to the German launch. The results signal growing revenue momentum for the therapy as it expands into new markets.
Acadia reported Q3 2026 DAYBUE net sales of US$140 million, up 39% from Q3 2025 and 12% from Q2 2026, while Neuren's Q3 royalty income rose 51% to US$16.4 million. Acadia's full-year 2026 global net sales guidance is US$505 million to US$520 million, and the unresolved question is how the planned Japan submission will affect those projections.
The players
Neuren Pharmaceuticals
An Australian biopharmaceutical company that develops treatments for neurodevelopmental disorders and receives royalties from trofinetide sales.
Acadia Pharmaceuticals
A US biopharmaceutical company that commercializes DAYBUE (trofinetide) and reports its global net sales.
The details
Neuren received a US$35 million milestone payment after DAYBUE launched in Germany in October 2026, and its anticipated full-year 2026 royalty income was adjusted to US$56 million to US$58 million. A new US patent covering weight-banded dosing of trofinetide was also allowed, extending intellectual property protection until March 2041.
Timeline
October 2026: DAYBUE launched in Germany, triggering a US$35 million milestone payment.
Q3 2026: Acadia reported DAYBUE net sales of US$140 million.
November 5, 2026: Neuren announced the upgraded full-year 2026 guidance.
2027: Neuren plans to submit trofinetide for regulatory review in Japan.
March 2041: The newly allowed US patent extends IP protection to this date.
Health Landscape
Trofinetide, approved as DAYBUE for Rett syndrome, is now expanding from its US launch into European markets and a planned Japanese submission in 2027. The guidance upgrade shows that commercial uptake is outpacing earlier projections as the therapy moves into new regions.
For families managing Rett syndrome, expanding availability of trofinetide in Germany and planned approval in Japan could broaden access to treatment over time. The patent extension to 2041 also indicates that the therapy is expected to remain on the market for an extended period.
The takeaway
Strong commercial results for trofinetide suggest that treatments for rare neurological conditions can build meaningful revenue as they reach new markets. Readers following Rett syndrome care should watch for regulatory updates in Japan and Europe.
What happens next
Neuren plans to submit trofinetide for regulatory review in Japan in 2027, with a potential Japanese launch in 2028 subject to approval.
Further reading
Explore more research on Alzheimer’s treatments and the therapies moving through development.
Source note: This article includes information reported by Finance News Network.
